Drug Trial Radar · NCT02046434
Phenylbutyrate Response as a Biomarker for Alpha-synuclein Clearance From the Brain
Last checked: Nov 20, 2026Latest source record: Apr 25, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
38
Actual
Start
Jan 2014
Primary completion
Sep 2019
Study completion Sep 2019
Sponsor
- Lead sponsor
- University of Colorado, DenverAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 27, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 21 years, up to 80 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase I clinical trial of the FDA approved drug Glycerol Phenylbutyrate to see if phenylbutyrate can increase the removal of alpha-synuclein from the brain into the bloodstream. Alpha-synuclein forms abnormal protein deposits in dopamine neurons and is believed to cause the death of brain cells, leading to Parkinson's Disease.
Conditions
- Parkinson's Disease
Interventions
Glycerol PhenylbutyrateDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Levels of alpha-synuclein in blood plasmaTime frame: 1 month
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Colorado Denver Anschutz Medical Center
Aurora, Colorado
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.